Risks and Limitations to Keep in Mind Because the microdosing trend with tirzepatide is ahead of the research curve, it introduces unique unknowns beyond the usual GLP-1 risks
Diabetes Therapy, 2021 A meta-analysis of cardiovascular outcomes trials showing that GLP-1 receptor agonists improve heart health in patients with type 2 diabetes, with dosing levels influencing tolerability and side effect profiles
As the next phase of this research, more sophisticated in vivo models, incorporating chronic injury paradigms, long-term follow-ups, and genetic or pharmacological modifications of inflammatory pathways, will be critical to substantiate the translational potential of this approach
& Duijvestijn, Y
By the stable stage , the situation settles down
Perlas A, Mitsakakis N, Liu L et al